Curated News
By: NewsRamp Editorial Staff
October 26, 2026
Viromed Medical Raises EUR 2 Million in Capital Increase
TLDR
- Viromed Medical AG raised EUR 2 million at EUR 4.50 per share to strengthen working capital and accelerate cold plasma technology growth.
- Viromed Medical AG placed 450,000 new shares at EUR 4.50 each, increasing share capital to EUR 21.7 million using Authorized Capital 2025.
- Viromed Medical AG's capital increase supports advancing cold plasma technology in medicine, potentially improving patient care and treatment outcomes.
- Viromed Medical AG issued 450,000 new shares at EUR 4.50 each, raising EUR 2 million to fund working capital and cold plasma innovation.
Impact - Why it Matters
This capital increase provides Viromed Medical AG with approximately EUR 2 million in fresh working capital, which is crucial for a growth-oriented medical technology company. The funds will support the company's operations and help accelerate the adoption of its cold plasma technology in the medical field. For investors and stakeholders, the successful placement of shares at EUR 4.50 each signals confidence in Viromed's business model and growth prospects. The exclusion of subscription rights may dilute existing shareholders, but the influx of capital strengthens the company's balance sheet and enables it to pursue its strategic goals. As cold plasma technology gains traction in medicine, Viromed's strengthened financial position could lead to expanded market reach and potentially improved patient outcomes through innovative medical products.
Summary
Viromed Medical AG, a German medical products company listed on the stock exchange since October 2022, has successfully completed a capital increase announced on October 26, 2026. The company placed 450,000 new registered no-par value shares at a placement price of EUR 4.50 per share, raising gross proceeds of approximately EUR 2 million. The funds are earmarked to finance the company's working capital. Subject to registration in the commercial register, Viromed's share capital will increase from EUR 21,250,000 to EUR 21,700,000. The capital increase was executed by partially utilizing the Authorized Capital 2025 and excluded shareholders' subscription rights.
Viromed Medical AG specializes in the development, manufacture, and distribution of medical products. Its operating business focuses on distributing innovative cold plasma technology for medical applications through its wholly owned subsidiary, Viromed Medical GmbH. The company serves a broad customer base in the DACH region and beyond. Viromed aims to further advance the use of cold plasma technology in medicine and realize corresponding growth potential in the coming years. For more information, visit www.viromed-medical-ag.de.
The capital increase underscores Viromed's commitment to strengthening its financial position and supporting its operating activities. With the additional working capital, the company is better positioned to execute its growth strategy and expand the adoption of cold plasma technology in medical settings. The transaction was completed with the exclusion of subscription rights, indicating a targeted approach to raising funds from specific investors. Viromed's focus on innovation and market expansion in the medical technology sector remains central to its long-term objectives.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Viromed Medical Raises EUR 2 Million in Capital Increase
